The Spectrum of Cutaneous Adverse Events During Encorafenib and Binimetinib Treatment in B-Rapidly Accelerated Fibrosarcoma-Mutated Advanced Melanoma
November 2018
in “
Journal of the European Academy of Dermatology and Venereology
”
Studysummary In this study, encorafenib combined with binimetinib was well tolerated in melanoma patients, resulting in relatively few cutaneous adverse events compared to other BRAF and MEK inhibitors.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The study investigated cutaneous adverse events in melanoma patients treated with encorafenib and binimetinib at the University Hospital of Zurich. It found that encorafenib monotherapy resulted in fewer hyperproliferative skin issues compared to established BRAF inhibitors, but palmoplantar hyperkeratosis and erythrodysesthesia were more common. In patients treated with encorafenib alone (n=24), the most frequent adverse events were palmoplantar hyperkeratosis (54%), palmoplantar erythrodysesthesia (58%), and alopecia (46%). Binimetinib monotherapy (n=25) primarily caused drug-induced papulopustular eruptions. The combination therapy (n=49) was well tolerated, with palmoplantar hyperkeratosis occurring in 10% of patients. Overall, the combination of encorafenib and binimetinib induced few cutaneous adverse events.
